Zealand Pharma A/S (ZLDPF) Expected to Announce Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is projected to issue its results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of $0.1431 per share and revenue of $128.9080 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. On average, analysts expect Zealand Pharma A/S to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS:ZLDPF opened at $47.50 on Thursday. The business has a fifty day moving average of $45.40 and a 200-day moving average of $50.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12. The firm has a market cap of $3.40 billion, a PE ratio of 3.52 and a beta of 0.88.

Analyst Ratings Changes

A number of equities research analysts have commented on ZLDPF shares. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S has a consensus rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.